Taiwania Capital
| Industry | Venture capital |
|---|---|
| Founded | 2017 |
| Headquarters | Taipei, Taiwan |
| Key people | Lin Hsin-yi (chairman) |
| AUM | US$1 billion (2024) |
| Website | taiwaniacapital |
Taiwania Capital Management Corporation (Chinese: 台杉投資; traded as Taiwania Capital or simply Taiwania) is a Taiwanese venture capital firm headquartered in Taipei. Founded in 2017, the firm primarily invests in early stage companies.
History
Taiwania Capital was sponsored by the National Development Fund (40% ownership) and founded in August 2017. As of August 2021, it had raised about US$490 million (NT$13.75 billion) for five funds, with focuses in internet of things and biotechnology investments. In the firm's first four years, it made 34 investments, of which five had gone public.[1]
In 2022, Taiwania launched a $200 million fund to invest in Central and Eastern European companies.[2] The fund focuses on companies in Lithuania, the Czech Republic, and Slovakia.[3]
Wu Rong-i served as chairman from 2017 to 2024 and was succeeded by Lin Hsin-i. Under Wu's leadership, the firm invested in over 75 companies.[4]
Investments
Notable investments that have had IPOs include:
- Ambiq Micro[1]
- C4 Therapeutics[1]
- Fractyl Health[1]
References
- 1 2 3 4 Chen, Pi-fen (31 August 2021). "台杉秀亮眼投資成果 5上市公司市值逾1,500億". Commercial Times (in Chinese (Taiwan)). Retrieved 8 April 2026.
- ↑ Bartlett-Imadegawa, Rhyannon (24 June 2023). "Taiwan-backed fund invests in Central, Eastern Europe as ties warm". Nikkei Asia. Retrieved 8 April 2026.
- ↑ "Lithuanian fintech firm receives $10m investment from Taiwan fund". LRT. 10 April 2024. Retrieved 8 April 2026.
- ↑ Wu, Hsin-tian (30 July 2024). "賀吳榮義卸任台杉董座 蔡英文分享退休生活：找到生活節奏最重要". Liberty Times (in Chinese (Taiwan)). Retrieved 8 April 2026.